Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients

被引:0
作者
Marie Jakobsen
Mette Dalsgaard
Morten Hørmann
Daniél Vega Møller
机构
[1] COWI A/S,
[2] Novo Nordisk Scandinavia AB,undefined
来源
BMC Endocrine Disorders | / 12卷
关键词
Insulin detemir; Insulin glargine; Type 2 diabetes; Dose; Health care costs;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 77 条
[1]  
Mudaliar S(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853
[2]  
Edelman SV(2001)Insulin therapy in type 2 diabetes Endocrinol Metab Clin North Am 30 935-982
[3]  
Meneghini L(2008)Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient Int J Clin Pract 62 1255-1264
[4]  
Bullano MF(2005)Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Curr Med Res Opin 21 291-298
[5]  
Al-Zakwani IS(2007)Towards peakless, reproducible and long-acting insulins An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 9 648-659
[6]  
Fisher MD(2001)Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy Diabetes Care 24 296-301
[7]  
Menditto L(2006)A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 29 1269-1274
[8]  
Willey VJ(2006)Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 28 1569-1581
[9]  
Heise T(2008)An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update) Expert Opin Pharmacother 9 2181-2195
[10]  
Pieber TR(2008)A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 30 1976-1987